IM156

Research use only, not for human use.

IM156 is an orally bioavailable mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity.

IM156 is an orally bioavailable mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. IM156, a new metformin derivative, formerly known as HL156A, has been reported to ameliorate various types of fibrosis and inhibit in vitro and in vivo tumors by inducing AMPK activation more potently than metformin. In vivo treatment of IM156 exacerbated the memory differentiation of virus-specific CD8+ T cells, resulting in an increase in short-lived effector cells but decrease in memory precursor effector cells. Thus, IM156 treatment impaired the function of virus-specific memory CD8+ T cells, indicating that excessive AMPK activation weakens memory T cell differentiation, thereby suppressing recall immune responses.

——

——

——

Others

Other Targets

oxidative phosphorylation (OXPHOS)

——

——

1422365-93-2

315.13

C13H16F3N5O?

>98% (HPLC)

——

FC(F)(F)Oc1ccc(NC(=N)NC(=N)N2CCCC2)cc1

——

(-20℃)

With Ice Pack

≥ 2 years